Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

But the promise of CRISPR technology has yet to be fulfilled ... $4.1 billion Beta-thalassemia, sickle cell disease, cancer, cardiovascular diseases, diabetes Editas Medicine (NASDAQ:EDIT ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Everything you need to know about agonising sickle cell disease and the ‘revolutionary’ new DNA therapy that's being rolled ...

In the last decade, there has also been rapid development and interest in CRISPR/Cas9 technology and ... devastating diseases such as sickle cell disease and thalassemia. Beta-thalassemia is ...

Vertex Pharmaceuticals aims to use CRISPR Therapeutics’ gene-editing technology to develop ... based therapy are underway in sickle cell disease and beta thalassemia.

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...